The decrease in BTAF expression following JQ1 treatment led to an increase in glycolysis and OXPHOS, which maintain CD8+ T cells with features of stem cell-like and central memory phenotypes, and co-administration of JQ1 with CAR T-cells enhanced their anti-tumor activity and persistence in vivo. Here, CD8A is linked to neoplasm.